# Cytosorbents Corporation (CTSO)

Source: https://www.quantisnow.com/company/CTSO
Generated: 2026-11-10T11:15:55.251Z

- Ticker: CTSO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- SEC CIK: 0001175151
- Website: cytosorbents.com

## About

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.

## Latest CTSO news and filings

- 2026-11-09 12:00 UTC [CytoSorbents to Participate at the 2026 Jefferies Global Healthcare Conference in London](https://www.quantisnow.com/insight/cytosorbents-to-participate-at-the-2026-jefferies-global-healthcare-conference-6780105)
- 2026-10-29 11:00 UTC [Earnings Date] [CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/cytosorbents-to-report-third-quarter-2026-financial-results-and-recent-6762383)
- 2026-09-30 11:00 UTC [CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care](https://www.quantisnow.com/insight/cytosorbents-announces-new-data-presentations-at-upcoming-international-conferences-in-6729881)
- 2026-09-23 11:30 UTC [SEC Form 8-K] [Cytosorbents Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cytosorbents-corporation-filed-sec-form-8-k-regulation-fd-disclosure-other-6723605)
- 2026-09-23 11:00 UTC [CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://www.quantisnow.com/insight/cytosorbents-regains-compliance-with-nasdaq-minimum-bid-price-requirement-6723572)
- 2026-09-16 21:30 UTC [Insider Buy] [Chief Executive Officer Chan Phillip P. bought $22,644 worth of shares (3,774 units at $6.00), increasing direct ownership by 4% to 100,996 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-chan-phillip-p-bought-22644-worth-of-6717992)
- 2026-09-16 20:05 UTC [Insider Buy] [President and COO Capponi Vincent bought $12,537 worth of shares (2,073 units at $6.05), increasing direct ownership by 5% to 40,387 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-coo-capponi-vincent-bought-12537-worth-of-shares-6717488)
- 2026-09-16 20:05 UTC [Insider Buy] [Director Sobel Alan D. bought $15,254 worth of shares (2,500 units at $6.10), increasing direct ownership by 34% to 9,887 units (SEC Form 4)](https://www.quantisnow.com/insight/director-sobel-alan-d-bought-15254-worth-of-shares-2500-6717476)
- 2026-09-10 11:00 UTC [Conference Announcement] [CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/cytosorbents-to-present-at-the-hc-wainwright-28th-annual-global-6710783)
- 2026-09-09 20:05 UTC [Insider Buy] [Chief Executive Officer Chan Phillip P. bought $70,000 worth of shares (200,000 units at $0.35), increasing direct ownership by 11% to 1,944,432 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-chan-phillip-p-bought-70000-worth-of-6709970)
- 2026-09-08 20:05 UTC [SEC Form 8-K] [Cytosorbents Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cytosorbents-corporation-filed-sec-form-8-k-amendments-to-articles-of-6708234)
- 2026-09-03 11:00 UTC [CytoSorbents Announces Reverse Stock Split](https://www.quantisnow.com/insight/cytosorbents-announces-reverse-stock-split-6704151)
- 2026-09-02 11:28 UTC [CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings](https://www.quantisnow.com/insight/cytosorbents-announces-new-real-world-data-demonstrating-significant-reduction-in-severe-6702279)
- 2026-08-07 20:06 UTC [SEC Form 8-K] [Cytosorbents Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cytosorbents-corporation-filed-sec-form-8-k-regulation-fd-disclosure-financial-6671501)
- 2026-08-06 20:25 UTC [Earnings Date] [CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update](https://www.quantisnow.com/insight/cytosorbents-reports-second-quarter-2026-financial-results-recent-business-highlights-6669475)
- 2026-08-06 20:19 UTC [SEC Form 8-K] [Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cytosorbents-corporation-filed-sec-form-8-k-results-of-operations-and-6669357)
- 2026-08-06 20:12 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Cytosorbents Corporation](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-cytosorbents-corporation-6669117)
- 2026-07-20 11:00 UTC [Earnings Date] [CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/cytosorbents-to-report-second-quarter-2026-financial-results-and-recent-6641843)
- 2026-07-06 20:05 UTC [SEC Form 8-K] [Cytosorbents Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/cytosorbents-corporation-filed-sec-form-8-k-notice-of-delisting-or-6628068)
- 2026-06-26 12:35 UTC [Conference Announcement] [Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing](https://www.quantisnow.com/insight/life-sciences-virtual-investor-forum-presentations-now-available-for-on-demand-6616806)
- 2026-06-25 20:45 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Cytosorbents Corporation](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-cytosorbents-corporation-6616142)
- 2026-06-25 20:43 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Cytosorbents Corporation](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-cytosorbents-corporation-6616120)
- 2026-06-25 13:26 UTC [SEC Form 8-K] [Cytosorbents Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cytosorbents-corporation-filed-sec-form-8-k-regulation-fd-disclosure-financial-6615417)
- 2026-06-23 12:35 UTC [Conference Announcement] [Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th](https://www.quantisnow.com/insight/life-sciences-virtual-investor-forum-agenda-announced-for-june-24th-6612016)
- 2026-06-18 12:46 UTC [Conference Announcement] [CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026](https://www.quantisnow.com/insight/cytosorbents-to-present-at-the-life-sciences-forum-on-june-6608085)
- 2026-06-16 11:00 UTC [Insider Buy] [Chief Financial Officer Mariani Peter J bought $44,000 worth of shares (100,000 units at $0.44), increasing direct ownership by 19% to 638,113 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-mariani-peter-j-bought-44000-worth-of-6603835)
- 2026-06-15 22:24 UTC [Insider Buy] [Chief Executive Officer Chan Phillip P. bought $104,898 worth of shares (261,469 units at $0.40), increasing direct ownership by 18% to 1,744,432 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-chan-phillip-p-bought-104898-worth-of-6603399)
- 2026-06-11 21:04 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Cytosorbents Corporation](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-cytosorbents-corporation-6598866)
- 2026-05-13 20:21 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Cytosorbents Corporation](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-cytosorbents-corporation-6551112)
- 2026-05-13 20:05 UTC [SEC Form 8-K] [Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cytosorbents-corporation-filed-sec-form-8-k-results-of-operations-and-6550727)
- 2026-05-13 20:00 UTC [Earnings Date] [CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update](https://www.quantisnow.com/insight/cytosorbents-reports-first-quarter-2026-financial-results-recent-business-highlights-6550553)
- 2026-04-30 11:00 UTC [Earnings Date] [CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/cytosorbents-to-report-first-quarter-2026-financial-results-and-recent-6522674)
- 2026-04-15 21:18 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Cytosorbents Corporation](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-cytosorbents-corporation-6501675)
- 2026-04-02 11:00 UTC [SEC Form 8-K] [Cytosorbents Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/cytosorbents-corporation-filed-sec-form-8-k-notice-of-delisting-or-6483268)
- 2026-03-30 11:04 UTC [SEC Form 10-K] [SEC Form 10-K filed by Cytosorbents Corporation](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-cytosorbents-corporation-6475753)
- 2026-03-25 20:27 UTC [SEC Form 8-K] [Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cytosorbents-corporation-filed-sec-form-8-k-results-of-operations-and-6469076)
- 2026-03-25 20:05 UTC [Earnings Date] [CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/cytosorbents-reports-fourth-quarter-and-full-year-2025-financial-results-6468845)
- 2026-03-19 13:44 UTC [CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026](https://www.quantisnow.com/insight/cytosorbents-announces-hotswap-launch-renewed-aferetica-partnership-and-new-clinical-6460990)
- 2026-03-05 12:00 UTC [Earnings Date] [CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/cytosorbents-to-report-fourth-quarter-and-full-year-2025-financial-6431358)
- 2026-02-13 22:56 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Cytosorbents Corporation](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-cytosorbents-corporation-6393402)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CTSO
- Earnings history: https://www.quantisnow.com/earnings/CTSO
- Dividend history: https://www.quantisnow.com/dividends/CTSO
- Insider transactions: https://www.quantisnow.com/insiders/CTSO
- Options chain: https://www.quantisnow.com/options/CTSO
- SEC 8-K filings only: https://www.quantisnow.com/company/CTSO/8-k
- RSS and alerts for CTSO: https://www.quantisnow.com/docs/rss-feeds.md